Telix Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Telix Pharmaceuticals Limited
TLX Stock   15.76  0.16  1.03%   
Telix Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Telix Pharmaceuticals Limited investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Telix Pharmaceuticals financial statements helps investors assess Telix Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Telix Pharmaceuticals' valuation are summarized below:
Profit Margin
0.0762
Market Capitalization
5.3 B
Enterprise Value Revenue
12.7364
Revenue
645.7 M
Earnings Share
0.09
We have found one hundred twenty available fundamental trend indicators for Telix Pharmaceuticals Limited, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Telix Pharmaceuticals Limited current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 7.8 M in 2024. Working Capital is likely to drop to about (4.1 M) in 2024

Telix Pharmaceuticals Total Revenue

521.49 Million

Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 1.1 M, Depreciation And Amortization of 7.1 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Telix Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets253.4 M398.3 M183.5 M
Slightly volatile
Short and Long Term Debt Total9 M17.4 M4.2 M
Slightly volatile
Other Current Liabilities129.2 M123 M22.2 M
Slightly volatile
Total Current Liabilities82.7 M157.4 M38.9 M
Slightly volatile
Total Stockholder Equity85.3 M148.9 M79 M
Very volatile
Property Plant And Equipment Net16.6 M30.5 M8.4 M
Slightly volatile
Current Deferred Revenue117.6 M112 M26 M
Slightly volatile
Accounts Payable18.5 M32.8 M9.6 M
Slightly volatile
Cash93.4 M123.2 M80.8 M
Pretty Stable
Non Current Assets Total105.1 M173.5 M75.3 M
Slightly volatile
Non Currrent Assets Other359.7 K586 K233.2 K
Slightly volatile
Long Term Debt4.3 M8.2 M1.3 M
Slightly volatile
Cash And Short Term Investments93.4 M123.2 M80.8 M
Pretty Stable
Net Receivables37.4 M64.8 M19.8 M
Slightly volatile
Good Will5.1 M4.8 M4.4 M
Slightly volatile
Common Stock Shares Outstanding331.5 M323.7 M289.4 M
Slightly volatile
Liabilities And Stockholders Equity253.4 M398.3 M183.5 M
Slightly volatile
Non Current Liabilities Total85.3 M92 M65.6 M
Slightly volatile
Capital Lease Obligations5.4 M8.3 M2.9 M
Slightly volatile
Inventory18.2 M17.3 M3.6 M
Slightly volatile
Other Current Assets20.5 M19.5 M5.4 M
Slightly volatile
Total Liabilities168.1 M249.4 M104.5 M
Slightly volatile
Net Invested Capital88.8 M158.1 M80.4 M
Pretty Stable
Property Plant And Equipment Gross20 M36.3 M10.1 M
Slightly volatile
Short and Long Term Debt1.2 M1.1 M410.6 K
Slightly volatile
Total Current Assets148.3 M224.8 M108.3 M
Slightly volatile
Capital Stock317.7 M446.3 M209.6 M
Slightly volatile
Non Current Liabilities Other23 M12.2 M47.5 M
Slightly volatile
Net Working Capital65.5 M67.4 M69.4 M
Pretty Stable
Short Term Debt989.7 K1.6 M817.2 K
Slightly volatile
Intangible Assets72.8 M104.8 M59.2 M
Slightly volatile
Common Stock317.7 M446.3 M209.6 M
Slightly volatile
Long Term Investments9.8 M11 M12 M
Slightly volatile

Telix Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.1 M1 M188.5 K
Slightly volatile
Depreciation And Amortization7.1 M6.7 M1.1 M
Slightly volatile
Interest Expense7.1 M13.1 M3 M
Slightly volatile
Selling General Administrative57.5 M79 M29.8 M
Slightly volatile
Selling And Marketing Expenses57.6 M54.9 M9.9 M
Slightly volatile
Total Revenue521.5 M496.7 M82 M
Slightly volatile
Gross Profit323.9 M308.5 M50.6 M
Slightly volatile
Other Operating Expenses249.1 M496.7 M113.3 M
Slightly volatile
Research Development67.1 M128.8 M36.1 M
Slightly volatile
Cost Of Revenue197.6 M188.2 M31.5 M
Slightly volatile
Total Operating Expenses179.2 M308.5 M90.3 M
Slightly volatile
Reconciled Depreciation6.1 M6.7 M5.1 M
Slightly volatile

Telix Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow71.7 M116.3 M51.9 M
Slightly volatile
Capital Expenditures7.2 M10.8 M2.5 M
Slightly volatile
Issuance Of Capital Stock6.3 M6.7 M39 M
Very volatile
Total Cash From Financing Activities9.7 M10.2 M38.2 M
Very volatile
End Period Cash Flow93.4 M123.2 M80.8 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.410.434.8873
Slightly volatile
Days Sales Outstanding45.2347.6053202
Slightly volatile
Average Payables1.8 M3.2 M2.4 M
Slightly volatile
Capex To Depreciation0.180.30.2291
Slightly volatile
Inventory Turnover9.2410.86988.8534
Slightly volatile
Days Of Inventory On Hand67.1333.579178.8968
Slightly volatile
Payables Turnover11.125.7311.2357
Slightly volatile
Average Inventory2 M1.7 M2.4 M
Slightly volatile
Research And Ddevelopement To Revenue0.250.25944.1406
Slightly volatile
Capex To Revenue0.03780.02170.0437
Slightly volatile
Cash Per Share0.0880.05990.0929
Very volatile
Days Payables Outstanding60.5163.6995221
Slightly volatile
Intangibles To Total Assets0.290.27530.1514
Slightly volatile
Current Ratio0.91.42841.0633
Slightly volatile
Receivables Turnover7.067.66727.2063
Slightly volatile
Graham Number0.790.831.9189
Very volatile
Capex Per Share0.04010.04220.0453
Pretty Stable
Average Receivables7.5 M7.1 M4.4 M
Slightly volatile
Revenue Per Share2.351.912.6101
Very volatile
Interest Debt Per Share0.180.190.4736
Very volatile
Debt To Assets0.02190.0230.1884
Slightly volatile
Operating Cycle77.1381.1844275
Slightly volatile
Days Of Payables Outstanding60.5163.6995221
Slightly volatile
Quick Ratio0.781.31850.9041
Slightly volatile
Net Income Per E B T1.251.6881.2179
Slightly volatile
Cash Ratio0.440.78290.5111
Slightly volatile
Cash Conversion Cycle16.6117.48553.3365
Pretty Stable
Days Of Inventory Outstanding67.1333.579178.8968
Slightly volatile
Days Of Sales Outstanding45.2347.6053202
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.090.981.2483
Very volatile
Fixed Asset Turnover12.3416.287610.9069
Pretty Stable
Debt Ratio0.02190.0230.1884
Slightly volatile
Price Sales Ratio0.410.434.8873
Slightly volatile
Asset Turnover1.451.24691.3777
Slightly volatile

Telix Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.8 M8.2 M137 M
Slightly volatile
Enterprise Value8.6 M9 M139.4 M
Slightly volatile

Telix Fundamental Market Drivers

Forward Price Earnings76.9231
Cash And Short Term Investments123.2 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue112 M117.6 M
Total Revenue496.7 M521.5 M
Cost Of Revenue188.2 M197.6 M
Sales General And Administrative To Revenue 0.16  0.15 
Research And Ddevelopement To Revenue 0.26  0.25 
Capex To Revenue 0.02  0.04 
Revenue Per Share 1.91  2.35 
Ebit Per Revenue 0.03  0.04 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY